ZyVersa Therapeutics' CSO, Nicholas A. LaBella, Jr., to Present at the 3rd Annual Chronic Kidney Disease Drug Development Summit Being Held Virtually March 2-4, 2021

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Return to homepage

ZyVersa Therapeutics' CSO, Nicholas A. LaBella, Jr., to Present at the 3rd Annual Chronic Kidney Disease Drug Development Summit Being Held Virtually March 2-4, 2021

ZyVersa is well positioned in the rapidly emerging inflammasome space with a highly differentiated inflammasome inhibitor (IC 100), and in kidney disease with a first-in-class phase 2a-ready cholesterol efflux mediator (VAR 200) for treatment of orphan renal disease FSGS and other kidney diseases (Alport Syndrome, DKD)

PR Newswire

WESTON, Fla., Feb. 26, 2021

WESTON, Fla., Feb. 26, 2021 /PRNewswire/ -- ZyVersa Therapeutics, Inc. (ZyVersa), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that Nicholas A. LaBella, Jr., Chief Scientific Officer and Senior VP Research and Development, is an invited speaker at the 3rd Annual Chronic Kidney Disease Drug Development Summit being held virtually March 2-4, 2021. Mr. LaBella's presentation will address the role of renal lipids in the pathogenesis of kidney disease, and the potential of mediating cholesterol efflux as a therapeutic approach. To learn about renal lipids and kidney disease, please download a white paper by Clicking Here.

To learn about renal lipids and kidney disease, please visit ZyVersa.com/renal-lipids.

Details of Mr. LaBella's presentation follow:
Date: Tuesday, March 2, 2021
Time: 11:00 AM EST.

About ZyVersa Therapeutics, Inc.

ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. Our focus is on patients with inflammatory or renal diseases who have significant unmet medical needs. Our development pipeline includes a novel inflammasome inhibitor with potential to treat multiple inflammatory diseases and phase 2a-ready, VAR 200, a cholesterol efflux mediator for treatment of a rare kidney disease, focal segmental glomerulosclerosis (FSGS). For more information, please visit www.zyversa.com.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/zyversa-therapeutics-cso-nicholas-a-labella-jr-to-present-at-the-3rd-annual-chronic-kidney-disease-drug-development-summit-being-held-virtually-march-2-4-2021-301236217.html

SOURCE ZyVersa Therapeutics, Inc.

Copyright CNW Group 2021

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).
LinkedIn
StockTwits
Twitter